Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$35.51 USD
+0.41 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $35.50 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Supernus Pharmaceuticals, Inc. has a market cap of $1.97B, which represents its share price of $35.10 multiplied by its outstanding shares number of 55.99M. As a small-cap company, SUPN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SUPN 35.51 +0.41(1.15%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for SUPN
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics | SUPN Stock News
Supernus completes acquisition of Sage Therapeutics
Biogen rises as Alzheimer’s therapy drives Q2 beat
Supernus (SUPN) Receives Upgrade and Increased Price Target
Supernus (SUPN) Receives Upgrade from Cantor Fitzgerald